Calmare Therapeutics G.S.A Contract Extended Through the First Quarter of 2016
September 16, 2015
Contract Extension To be Replaced on New Contract Award Date

Fairfield, CT – September 16, 2015 – Calmare Therapeutics Incorporated, (OTCQB: CTTC) (CTI), the Calmare® pain mitigation company, has been issued a six-month bilateral contract modification of its General Services Administration (GSA) military contract (V797P-4300B).

"We are very encouraged about the state of CTI’s military program," said Calmare Therapeutics President & CEO Conrad Mir. "As always, given budgets and processes of any U.S. governmental agency, we received this extension as we point towards a permanent agreement. During the next six months, we will work diligently to reach the goal we set and announced over 14 months ago – the gaining of a multi-million dollar military contract. In the meantime, it is our intent to treat as many military personnel suffering from chronic pain as possible while adding further proof of the efficacy Calmare Pain Mitigation Therapy."

Calmare Pain Mitigation Therapy and its U.S. Military

Since receiving its first GSA Contract in 2010, Calmare Pain Mitigation Therapy (PMT) has successfully helped our Nation’s military personnel experience unparalleled chronic pain relief without the need for prescription drugs. Calmare PMT offers comprehensive pain mitigation whereby pain may be eliminated for well over 3 to 4 months after the first full treatment regimen in those patients that are responders. With one or two booster treatments after the first course, a patient may have full pain elimination for a year of more.

About the Company

Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy company, researches, develops and commercializes its flagship medical device - the non-invasive and non-addictive Calmare® Pain Therapy device. The company holds the U.S. Food & Drug Administration 510k clearance on its device, which grants it the exclusive right to sell, market, research and develop the medical device. Calmare devices are commercially sold to medical practices throughout the world. They are also found on U.S. military hospitals, clinics and installations via CTI’s General Services Administration (GSA) military contract (V797P-4300B).

Forward-Looking Statement

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Direct inquiries to
Conrad F. Mir
Calmare Therapeutics Incorporated
2 Trap Falls Rd. STE 507
Shelton, CT 06484
Email: This email address is protected. Javascript must be enabled to view it.
Tel: 203.712.7893